South African authorities are investigating Johnson & Johnson and its Janssen subsidiary over “excessive pricing” of a lifesaving tuberculosis drug, the latest imbroglio to engulf the company over its medicine.
In a brief statement, the South African Competition Commission confirmed that it lodged a complaint earlier this week against the health care giant over its TB medicine, bedaquiline, which is also sold under the Sirturo brand name. The regulator did not provide any details other than to say it has information suggesting a “reasonable suspicion” the company may also have engaged in “exclusionary practices.”
We asked J&J for comment and will update you accordingly.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect